The Clinical Biospecimen and Research Core

临床生物样本和研究核心

• 批准号: 10443135
• 负责人: Julian Abrams
• 金额: $ 23.82万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-30 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10443135
• 关键词: Agreement; Area; Basic Science; Bioinformatics; Biometry; Cancer Center; Cell Culture Techniques; Cell Nucleus; Clinical; Clinical Data; Clinical Investigator; Clinical Research; Clinical effectiveness; Collaborations; Collection; Consultations; Custom; Data; Data Element; Databases; Digestive System Disorders; Disease; Educational workshop; Electronic Health Record; Ensure; Epithelial Cells; Feedback; Fertilization; Freezing; Funding; Goals; Homeostasis; Human; Human Subject Research; Image; Immunologic Monitoring; Infrastructure; Interdisciplinary Study; Leadership; Link; Liver diseases; Longevity; Mission; Modeling; Organ; Organoids; Patient Selection; Patients; Quality Control; RNA; Records; Research; Research Design; Research Personnel; Research Support; Resources; Sampling; Science; Scientist; Services; Small Nuclear RNA; Specimen; Structure; Surveys; Tissue Microarray; Tissues; Training; Training and Education; Translational Research; United States National Institutes of Health; Universities; Work; base; biobank; bioimaging; cellular imaging; cost effective; data integration; data management; histopathological examination; human subject; innovation; interest; meetings; member; next generation; novel; operation; patient population; prevent; programs; repository; single cell analysis; symposium; transcriptome sequencing; translational study

PROJECT SUMMARY The overall goal of the Clinical Biospecimen and Research Core (CBRC) is to facilitate the conduct of clinical and translational studies in the Columbia University Digestive and Liver Disease Research Center (CU-DLDRC). The CBRC will provide research navigation services to its members to access extensive collections and storage of digestive organ biospecimens. This resource will also combine biospecimen collection and analysis with comprehensive clinical data elements. In concert with other CU-DLDRC Biomedical Cores, CBRC will enable state-of-the-art single cell, imaging and organoid modelling-based analyses of its biospecimens through multi- core workflows, thereby linking to the central theme “Epithelial Cells and Their Interactions in Digestive Homeostasis and Disease” in human relevant settings. Through collaborative agreements with established structures in the Cancer Center and Human Immune Monitoring cores, we will offer subsidized services such as single nucleus RNA-sequencing, tissue microarrays, expert histopathological examination and biostatistical support, thereby enhancing the capability of the CU-DLDRC to conduct impactful translational research. Collaborative translational research and cross-fertilization between clinical and basic investigators in the CU- DLDRC will be fertilized through a central infrastructure and consultative services for clinical research design and application under the umbrella of organ-specific clinical-basic teams. The organ-specific clinical-basic teams will support the analysis of CBRC-provided biospecimens in the CU-DLDRC biomedical cores through combined clinical and basic expertise and dialogue, and vice versa, will bring novel basic research concepts from bench to beside. The CBRC will led by two highly qualified NIH-funded clinical investigators, Dr. Julian Abrams (Director) and Dr. Elizabeth Verna (Associate Director). The following Specific Aims will maximize benefits and added value to CU-DLDRC members and contribute to the mission of the CU-DLDRC: To provide comprehensive biobanking of digestive organ biospecimens with linked clinical data (Aim 1); to enable state-of-the-art translational analyses of clinical samples (Aim 2); and to provide tailored human subjects research training, education, and biostatistical support (Aim 3). According to user surveys, 96% of CU-DLDRC researchers plan to utilize CBRC services. In conclusion, the CBRC will provide a crucial interface between clinical and basic CU-DLDRC investigators that does not exist in this form at Columbia and promote high quality collaborative translational research through access to a wealth of biospecimens. Through these services, the CBRC will provide major benefits to basic and clinical CU-DLDRC researchers alike.

项目摘要 临床生物样本和研究中心（CBRC）的总体目标是促进临床生物样本和研究中心的开展。 在哥伦比亚大学消化和肝脏疾病研究中心（CU-DLDRC）进行转化研究。 银监会将为其成员提供研究导航服务，以访问广泛的收藏和存储 消化器官的生物标本该资源还将结合联合收割机生物标本的收集和分析， 全面的临床数据元素。与其他CU-DLDRC生物医学核心一致，银监会将使 最先进的单细胞，成像和类器官建模的分析，其生物标本，通过多， 核心工作流程，从而链接到中心主题“上皮细胞及其在消化系统中的相互作用 稳态和疾病”在人类相关的设置。通过与既定机构的合作协议 在癌症中心和人体免疫监测核心的结构，我们将提供补贴服务，如 单核RNA测序，组织微阵列，专家组织病理学检查和生物统计学 支持，从而提高CU-DLDRC进行有影响力的转化研究的能力。 协作转化研究和交叉施肥之间的临床和基础研究人员在CU- DLDRC将通过中央基础设施和临床研究设计咨询服务得到充实 在器官特异性临床基础团队的保护伞下进行应用。器官特异性临床基础团队 将支持分析CU-DLDRC生物医学核心中CBRC提供的生物标本， 临床和基础专业知识和对话，反之亦然，将带来新的基础研究概念，从板凳， 旁边。银监会将由两名高素质的NIH资助的临床研究者，朱利安艾布拉姆斯博士（主任） Elizabeth Verna博士（副主任）。以下具体目标将使效益和附加值最大化 向CU-DLDRC成员提供信息，并为CU-DLDRC的使命做出贡献：提供全面的生物库 消化器官生物标本与相关临床数据（目标1）;实现最先进的转化分析 临床样本（目标2）;并提供量身定制的人类受试者研究培训，教育和生物统计 支持（目标3）。根据用户调查，96%的CU-DLDRC研究人员计划使用银监会的服务。在 结论，银监会将在临床和基础CU-DLDRC研究者之间提供重要的接口， 不存在这种形式在哥伦比亚和促进高质量的合作转化研究，通过 获取丰富的生物标本通过这些服务，银监会将为基本和 临床CU-DLDRC研究人员一样。